These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25468910)

  • 61. Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases.
    Mineev KS; Bocharov EV; Pustovalova YE; Bocharova OV; Chupin VV; Arseniev AS
    J Mol Biol; 2010 Jul; 400(2):231-43. PubMed ID: 20471394
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation.
    Tanaka T; Zhou Y; Ozawa T; Okizono R; Banba A; Yamamura T; Oga E; Muraguchi A; Sakurai H
    J Biol Chem; 2018 Feb; 293(7):2288-2301. PubMed ID: 29255092
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Stimulation of the four isoforms of receptor tyrosine kinase ErbB4, but not ErbB1, confers cardiomyocyte hypertrophy.
    Wang Z; Chan HW; Gambarotta G; Smith NJ; Purdue BW; Pennisi DJ; Porrello ER; O'Brien SL; Reichelt ME; Thomas WG; Paravicini TM
    J Cell Physiol; 2021 Dec; 236(12):8160-8170. PubMed ID: 34170016
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis.
    Clayton AH; Walker F; Orchard SG; Henderson C; Fuchs D; Rothacker J; Nice EC; Burgess AW
    J Biol Chem; 2005 Aug; 280(34):30392-9. PubMed ID: 15994331
    [TBL] [Abstract][Full Text] [Related]  

  • 66. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases.
    Spencer KS; Graus-Porta D; Leng J; Hynes NE; Klemke RL
    J Cell Biol; 2000 Jan; 148(2):385-97. PubMed ID: 10648571
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Identification of a novel antagonist of the ErbB1 receptor capable of inhibiting migration of human glioblastoma cells.
    Staberg M; Riemer C; Xu R; Dmytriyeva O; Bock E; Berezin V
    Cell Oncol (Dordr); 2013 Jun; 36(3):201-11. PubMed ID: 23580313
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bipartite inhibition of Drosophila epidermal growth factor receptor by the extracellular and transmembrane domains of Kekkon1.
    Alvarado D; Rice AH; Duffy JB
    Genetics; 2004 May; 167(1):187-202. PubMed ID: 15166146
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
    Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
    Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Intensification of growth factor receptor signalling by phorbol treatment of ligand-primed cells implies a dimer-stabilizing effect of protein kinase C-dependent juxtamembrane domain phosphorylation.
    Gulliford T; Ouyang X; Epstein RJ
    Cell Signal; 1999 Apr; 11(4):245-52. PubMed ID: 10372802
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evolutionary analysis of the ErbB receptor and ligand families.
    Stein RA; Staros JV
    J Mol Evol; 2000 May; 50(5):397-412. PubMed ID: 10824084
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors.
    Brignola PS; Lackey K; Kadwell SH; Hoffman C; Horne E; Carter HL; Stuart JD; Blackburn K; Moyer MB; Alligood KJ; Knight WB; Wood ER
    J Biol Chem; 2002 Jan; 277(2):1576-85. PubMed ID: 11696537
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
    Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
    BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.
    Laederich MB; Funes-Duran M; Yen L; Ingalla E; Wu X; Carraway KL; Sweeney C
    J Biol Chem; 2004 Nov; 279(45):47050-6. PubMed ID: 15345710
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization.
    Hughes JB; Berger C; Rødland MS; Hasmann M; Stang E; Madshus IH
    Mol Cancer Ther; 2009 Jul; 8(7):1885-92. PubMed ID: 19584234
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes.
    Qian X; O'Rourke DM; Fei Z; Zhang HT; Kao CC; Greene MI
    J Biol Chem; 1999 Jan; 274(2):574-83. PubMed ID: 9872991
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction.
    Huang GC; Ouyang X; Epstein RJ
    Biochem J; 1998 Apr; 331 ( Pt 1)(Pt 1):113-9. PubMed ID: 9512468
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.
    Zhang X; Pickin KA; Bose R; Jura N; Cole PA; Kuriyan J
    Nature; 2007 Nov; 450(7170):741-4. PubMed ID: 18046415
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Desensitization by different strategies of epidermal growth factor receptor and ErbB4.
    Yamamoto H; Higa-Nakamine S; Noguchi N; Maeda N; Kondo Y; Toku S; Kukita I; Sugahara K
    J Pharmacol Sci; 2014; 124(3):287-93. PubMed ID: 24553453
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.
    Komurasaki T; Toyoda H; Uchida D; Morimoto S
    Oncogene; 1997 Dec; 15(23):2841-8. PubMed ID: 9419975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.